08/11/2024  22:00:00 Chg. +3.9400 Volume Bid00:04:31 Demandez à00:04:31 Capitalisation boursière Dividende Y. Rapport P/E
828.4200USD +0.48% 563,585
Chiffrre d'affaires: 272.09 Mio.
828.5000Bid taille: 100 855.0000Ask la taille: 100 91.03 Mrd.USD - 22.36

Description de l'entreprise

Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases.
 

Conseil d'administration & Conseil de surveillance

PDG
Dr. Leonard S. Schleifer
Conseil d'administration
Robert E. Landry, Dr. George D. Yancopoulos
Conseil de surveillance
Arthur F. Ryan, Christine A. Poon, Craig B. Thompson, Dr. Bonnie L. Bassler, Dr. George D. Yancopoulos, Dr. Leonard S. Schleifer, Dr. Marc Tessier-Lavigne, George L. Sing, Huda Y. Zoghbi, M.D., Joseph L. Goldstein, M.D., Michael S. Brown, M.D., Tony Coles, M.D.
 

Données de l'entreprise

Nom: Regeneron Pharmaceuticals Inc.
Adresse: 777 Old Saw Mill River Road,Tarrytown, New York 10591-6707, USA
Téléphone: +1-914-847-7000
Fax: -
Courriel: -
Internet: is.gd/sEAmh8
Industrie: Biotechnology
Secteur: Biotechnology
Sous-secteur: Biotechnology
Fin de l'exercice financier: 31/12
Flotte libre: 68.40%
IPO date: 12/04/1991

Relations avec les investisseurs

Nom: -
Téléphone IR: +1-914-847-7741
IR-Fax: -
E-mail IR: invest@regeneron.com

Principaux actionnaires

Autres
 
50.26%
FMR LLC.
 
9.52%
Vanguard Group
 
8.16%
BlackRock Inc.
 
7.96%
JP Morgan Chase & Co.
 
6.67%
Capital World Investors
 
4.73%
State Street Corporation
 
4.52%
Capital International Investors
 
2.69%
Dodge & Cox
 
2.18%
Autres
 
3.30%